首页> 外文期刊>Oncology letters >High expression levels of class III beta-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy
【24h】

High expression levels of class III beta-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy

机译:在切除的非小细胞肺癌患者中高表达的III类β-微管蛋白水平预示了长春瑞滨辅助化疗后患者生存期的改善

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of the present study was to determine the frequency and predictive value of the expression of tumor microtubule components in patients with resected non-small cell lung cancer (R-NSCLC) subsequently treated with vinorelbine-based adjuvant chemotherapy. The expression of the microtubule components was evaluated in 85 R-NSCLC tumor samples using immunohistochemistry. All patients received vinorelbine-based chemotherapy. The predictive value of microtubule protein expression for disease-free survival (DFS) and overall survival (OS) was assessed. The expression of the microtubule components was not associated with any baseline clinicopathological factors in the R-NSCLC patients. High tumor expression levels of class III beta-tubulin were correlated with an improved DFS (P=0.033) and a trend towards a longer OS (P=0.226). Class II and IV beta-tubulins were not correlated with patient outcome. Multivariate analysis of factors, including gender, age, histology, stage and class II, III and IV P-tubulin expression demonstrated that high levels of class III P-tubulin expression were correlated independently with DFS (P=0.031). These findings suggest that high class III beta-tubulin expression levels in resected tumors are predictive of improved DFS in R-NSCLC patients receiving vinorelbine-based chemotherapy.
机译:本研究的目的是确定随后接受长春瑞滨为基础的辅助化疗的非小细胞肺癌(R-NSCLC)切除患者的肿瘤微管成分表达的频率和预测价值。使用免疫组织化学评估了85个R-NSCLC肿瘤样品中微管成分的表达。所有患者均接受基于长春瑞滨的化疗。评估了微管蛋白表达对于无病生存期(DFS)和总体生存期(OS)的预测价值。 R-NSCLC患者中微管成分的表达与任何基线临床病理因素无关。 III类β-微管蛋白的高肿瘤表达水平与DFS改善(P = 0.033)和OS延长的趋势相关(P = 0.226)。 II类和IV类β微管蛋白与患者预后无关。多因素分析,包括性别,年龄,组织学,分期以及II,III和IV级P-微管蛋白表达,表明高水平的III类P-微管蛋白表达与DFS独立相关(P = 0.031)。这些发现表明,在接受长春瑞滨为基础化疗的R-NSCLC患者中,切除的肿瘤中高水平的III类微管蛋白表达水平可预示DFS会改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号